Clinical Trial Update: Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the safety, pharmacokinetics, and efficacy of the MYC-inhibitor OMO-103 in solid tumors, including pancreatic and colorectal cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Pancreatic Cancer

Drugs mentioned

• OMO-103

Snippet

Sponsor: Peptomyc S.L. | Conditions: Advanced Solid Tumors, Pancreatic Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-04-25